Business Context and Reporting Period
This Form 8-K was filed by Tocagen Inc. on November 21, 2018. The filing reports the entry into a material definitive agreement. Note: The request metadata references "Forte Biosciences, Inc.", but the filing text explicitly identifies the registrant as Tocagen Inc.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It details a financing arrangement with the following parameters:
- Agreement Type: Equity Distribution Agreement (At-The-Market Offering).
- Counterparty: Citigroup Global Markets Inc. (Sales Agent).
- Maximum Offering Size: Up to $30,000,000 in aggregate offering price.
- Commission: Up to 3.0% of the gross sales price of shares sold.
- Expense Reimbursement: Up to $50,000 for specified expenses.
Material Changes
The material change reported is the execution of the Equity Distribution Agreement on November 21, 2018. This agreement allows the Company to sell shares of its common stock from time to time through Citigroup. The Company retains the right to suspend offers or terminate the agreement at any time and has no obligation to sell any shares.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or management commentary on future performance. Key terms and conditions include:
- Sales may be made via ordinary brokers' transactions, including on The Nasdaq Stock Market.
- Citigroup will use reasonable efforts to sell shares based on the Company's instructions regarding price, time, or size limits.
- The Company may also sell shares to Citigroup as principal for its own account under a separate terms agreement.
- The offering is subject to the Company's shelf registration statement on Form S-3 (File No. 333-224880).
Investor Verification Checklist
- Verify the exact number of shares sold and proceeds received under this agreement in subsequent filings (e.g., Form 10-Q or 10-K).
- Confirm the current status of the agreement (active, suspended, or terminated) in recent disclosures.
- Review the full text of the Equity Distribution Agreement (Exhibit 10.1) for specific termination clauses and pricing parameters.
- Check for any subsequent prospectus supplements filed to update the offering details.